Overview

To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

Status:
COMPLETED

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution.

Phase:

PHASE2

Details

Lead Sponsor:

Suzhou Kintor Pharmaceutical Inc,

Collaborator:

Suzhou Koshine Biomedica, Inc.